KaydedilenlerDerginizi ekleyin

Dergiler / The Anatolian Journal of Cardiology / 2019 / Cilt: 21 - Sayı: 2

Is endocan a biochemical marker for asymptomatic target organ damage in hypertensive patients?

Mustafa Tarık AĞAÇ
Behlül KAHYAOĞLU
Muhammed Murat Necati AKSOY
Fatma Behice CİNEMRE
Mehmet Bülent VATAN
Yasemin GÜNDÜZ
Sayfa
76–82
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

No significant correlation was found between serumendocan levels and any of the continuous variables related to AOD, such as the pulse pressure, carotid intimae-media thickness, cardio-anklevascular index, ankle-brachial index, left ventricular mass index, Sokolow–Lyon index, Cornell voltage-duration product, and estimated glomerular filtration rate.Conclusion: Endocan may not serve as a useful biomarker at asymptomatic vascular stages of hypertension, despite its role in indicating diseaseseverity and inflammatory activation in advanced symptomatic CV and renal disease. (Anatol J Cardiol 2019; 21: 76-82)Keywords: endocan, asymptomatic target organ damage, hypertension

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Identification of the asymptomatic target organ damage (AOD) helps to stratify the overall risk of cardiovascular (CV) diseases andguides a treatment decision in hypertensive patients without a symptomatic CV or renal disease.
📊
Temel Bulgular & Veri:The endothelial-cell-specific molecule 1(endocan) is regarded as a novel marker of endothelial dysfunction.
💡
Sonuç & Katkı:No significant correlation was found between serumendocan levels and any of the continuous variables related to AOD, such as the pulse pressure, carotid intimae-media thickness, cardio-anklevascular index, ankle-brachial index, left ventricular mass index, Sokolow–Lyon index, Cornell voltage-duration product, and estimated glomerular filtration rate.Conclusion: Endocan may not serve as a useful biomarker at asymptomatic vascular stages of hypertension, despite its role in indicating diseaseseverity and inflammatory activation in advanced symptomatic CV and renal disease. (Anatol J Cardiol 2019; 21: 76-82)Keywords: endocan, asymptomatic target organ damage, hypertension
🔬Tür:Araştırma Makalesi
📍Kapsam:2019 Verileri
⚙️Değişkenler:Alan Parametreleri

Özet

Objective: Identification of the asymptomatic target organ damage (AOD) helps to stratify the overall risk of cardiovascular (CV) diseases andguides a treatment decision in hypertensive patients without a symptomatic CV or renal disease. The endothelial-cell-specific molecule 1(endocan) is regarded as a novel marker of endothelial dysfunction. Its release is increased in hypertensive patients, especially those withsymptomatic CV and renal disease. In the present study, we aimed to evaluate the endocan levels in asymptomatic hypertensive patients withor without AOD.Methods: The study included 132 asymptomatic hypertensive patients, and 101 of who had at least one AOD.Results: Serum endocan levels did not differ between patients with and without AOD (3.81±0.78 vs. 3.83±0.63 ng/mL, p=0.88). An analysis according to the presence of any specific AOD did not show any difference between groups. No significant correlation was found between serumendocan levels and any of the continuous variables related to AOD, such as the pulse pressure, carotid intimae-media thickness, cardio-anklevascular index, ankle-brachial index, left ventricular mass index, Sokolow–Lyon index, Cornell voltage-duration product, and estimated glomerular filtration rate.Conclusion: Endocan may not serve as a useful biomarker at asymptomatic vascular stages of hypertension, despite its role in indicating diseaseseverity and inflammatory activation in advanced symptomatic CV and renal disease. (Anatol J Cardiol 2019; 21: 76-82)Keywords: endocan, asymptomatic target organ damage, hypertension

🔖

Bu Makaleye Atıf Yap

AĞAÇ, M. T., KAHYAOĞLU, B., AKSOY, M. M. N., CİNEMRE, F. B., VATAN, M. B., GÜNDÜZ, Y. (2019). Is endocan a biochemical marker for asymptomatic target organ damage in hypertensive patients?. The Anatolian Journal of Cardiology, Cilt: 21 - Sayı: 2, 76–82. https://ajindex.com/articles/365755

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903- 13
  2. Perrone-Filardi P, Coca A, Galderisi M, Paolillo S, Alpendurada F, de Simone G, et al. Non-invasive cardiovascular imaging for evaluating subclinical target organ damage in hypertensive patients: A consensus paper from the European Association of Cardiovascular Imaging (EACVI), the European Society of Cardiology Council on Hypertension, and the European Society of Hypertension (ESH). Eur Heart J Cardiovasc Imaging 2017; 18: 945-60
  3. Sehestedt T, Jeppesen J, Hansen TW, Wachtell K, Ibsen H, TorpPedersen C, et al. Risk prediction is improved by adding markers of subclinical organ damage to SCORE. Eur Heart J 2010; 31: 883-91
  4. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159- 219
  5. Brandes RP. Endothelial dysfunction and hypertension. Hypertension 2014; 64: 924-8
  6. Gkaliagkousi E, Gavriilaki E, Triantafyllou A, Douma S. Clinical Significance of Endothelial Dysfunction in Essential Hypertension. Curr Hypertens Rep 2015; 17: 85
  7. Kali A, Shetty KS. Endocan: a novel circulating proteoglycan. Indian J Pharmacol 2014; 46: 579-83
  8. Balta S, Mikhailidis DP, Demirkol S, Ozturk C, Celik T, Iyisoy A. Endocan: A novel inflammatory indicator in cardiovascular disease? Atherosclerosis 2015; 243: 339-43
  9. Celık T, Balta S, Karaman M, Ahmet Ay S, Demırkol S, Ozturk C, et al. Endocan, a novel marker of endothelial dysfunction in patients with essential hypertension: comparative effects of amlodipine and valsartan. Blood Press 2015; 24: 55-60
  10. Xiong C, Zhao ZW, Chen ZY, Wu LZ, Luo YK, Hu FD, et al. Elevated Human Endothelial Cell-Specific Molecule-1 Level and Its Association With Coronary Artery Disease in Patients With Hypertension. J Investig Med 2015; 63: 867-70
  11. Wang XS, Yang W, Luo T, Wang JM, Jing YY. Serum endocan levels are correlated with the presence and severity of coronary artery disease in patients with hypertension. Genet Test Mol Biomarkers 2015; 19: 124-7
  12. Yilmaz MI, Siriopol D, Saglam M, Kurt